Cargando…

Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)

Background. Data concerning frequency of Osteonecrosis of Jaws (ONJ) are mostly based on single center experiences. Patients and Methods. Since 2005 a multidisciplinary study group collected data of cases of ONJ in patients treated with Bisphosphonates (BP) and observed in oncology and hematology ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Fusco, Vittorio, Galassi, Claudia, Berruti, Alfredo, Ortega, Cinzia, Ciuffreda, Libero, Scoletta, Matteo, Goia, Franco, Migliario, Mario, Baraldi, Anna, Boccadoro, Mario, Loidoris, Anastasios, Bertetto, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600177/
https://www.ncbi.nlm.nih.gov/pubmed/23533811
http://dx.doi.org/10.1155/2013/672027
_version_ 1782475598695759872
author Fusco, Vittorio
Galassi, Claudia
Berruti, Alfredo
Ortega, Cinzia
Ciuffreda, Libero
Scoletta, Matteo
Goia, Franco
Migliario, Mario
Baraldi, Anna
Boccadoro, Mario
Loidoris, Anastasios
Bertetto, Oscar
author_facet Fusco, Vittorio
Galassi, Claudia
Berruti, Alfredo
Ortega, Cinzia
Ciuffreda, Libero
Scoletta, Matteo
Goia, Franco
Migliario, Mario
Baraldi, Anna
Boccadoro, Mario
Loidoris, Anastasios
Bertetto, Oscar
author_sort Fusco, Vittorio
collection PubMed
description Background. Data concerning frequency of Osteonecrosis of Jaws (ONJ) are mostly based on single center experiences. Patients and Methods. Since 2005 a multidisciplinary study group collected data of cases of ONJ in patients treated with Bisphosphonates (BP) and observed in oncology and hematology centers of a regional network. Results. By December 2008, 221 cases were registered. We report details of 200 cases, identified after cross-checking reports from centres of medical oncology, haematology, and oral care. Primary neoplasm was breast cancer (39%), myeloma (32%), prostate cancer (16%), and other types of cancer (8%). In about 50% of the cases a history of dental extraction was present. Zoledronic acid was administered (alone or with other BP) to 178 patients (89%). Median time from first infusion to ONJ diagnosis was 21.0 (zoledronic acid only) and 39.0 months (pamidronate only). The number of ONJ cases per year was 3 in 2003, 21 in 2004, 58 in 2005, 60 in 2006, 37 in 2007, and 21 in 2008. Conclusion. The number of new ONJ cases in cancer and myeloma patients increased until 2006 and then reduced. The possible reasons of this trend (introduction of zoledronic acid; increase of ONJ awareness; diffusion of preventive dental measures; late modifications of BP prescription) are herein discussed.
format Online
Article
Text
id pubmed-3600177
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36001772013-03-26 Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy) Fusco, Vittorio Galassi, Claudia Berruti, Alfredo Ortega, Cinzia Ciuffreda, Libero Scoletta, Matteo Goia, Franco Migliario, Mario Baraldi, Anna Boccadoro, Mario Loidoris, Anastasios Bertetto, Oscar ISRN Oncol Clinical Study Background. Data concerning frequency of Osteonecrosis of Jaws (ONJ) are mostly based on single center experiences. Patients and Methods. Since 2005 a multidisciplinary study group collected data of cases of ONJ in patients treated with Bisphosphonates (BP) and observed in oncology and hematology centers of a regional network. Results. By December 2008, 221 cases were registered. We report details of 200 cases, identified after cross-checking reports from centres of medical oncology, haematology, and oral care. Primary neoplasm was breast cancer (39%), myeloma (32%), prostate cancer (16%), and other types of cancer (8%). In about 50% of the cases a history of dental extraction was present. Zoledronic acid was administered (alone or with other BP) to 178 patients (89%). Median time from first infusion to ONJ diagnosis was 21.0 (zoledronic acid only) and 39.0 months (pamidronate only). The number of ONJ cases per year was 3 in 2003, 21 in 2004, 58 in 2005, 60 in 2006, 37 in 2007, and 21 in 2008. Conclusion. The number of new ONJ cases in cancer and myeloma patients increased until 2006 and then reduced. The possible reasons of this trend (introduction of zoledronic acid; increase of ONJ awareness; diffusion of preventive dental measures; late modifications of BP prescription) are herein discussed. Hindawi Publishing Corporation 2013-02-27 /pmc/articles/PMC3600177/ /pubmed/23533811 http://dx.doi.org/10.1155/2013/672027 Text en Copyright © 2013 Vittorio Fusco et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Fusco, Vittorio
Galassi, Claudia
Berruti, Alfredo
Ortega, Cinzia
Ciuffreda, Libero
Scoletta, Matteo
Goia, Franco
Migliario, Mario
Baraldi, Anna
Boccadoro, Mario
Loidoris, Anastasios
Bertetto, Oscar
Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)
title Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)
title_full Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)
title_fullStr Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)
title_full_unstemmed Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)
title_short Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)
title_sort decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the oncology network of piedmont and aosta valley (north-western italy)
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600177/
https://www.ncbi.nlm.nih.gov/pubmed/23533811
http://dx.doi.org/10.1155/2013/672027
work_keys_str_mv AT fuscovittorio decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT galassiclaudia decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT berrutialfredo decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT ortegacinzia decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT ciuffredalibero decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT scolettamatteo decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT goiafranco decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT migliariomario decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT baraldianna decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT boccadoromario decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT loidorisanastasios decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly
AT bertettooscar decreasingfrequencyofosteonecrosisofthejawincancerandmyelomapatientstreatedwithbisphosphonatestheexperienceoftheoncologynetworkofpiedmontandaostavalleynorthwesternitaly